Cerebrospinal fluid mitochondrial DNA levels in patients with multiple sclerosis

Nicolas Fissolo, Laura Cervera-Carles, Luisa María Villar Guimerans, Alberto Lleó, Jordi Clarimón, Jelena Drulovic, Irena Dujmovic, Margarete Voortman, Michael Khalil, Elia Gil, Laura Navarro, Jose Carlos Álvarez-Cermeño, Xavier Montalban, Manuel Comabella

Research output: Contribution to journalArticleResearch

4 Citations (Scopus)


© The Author(s), 2018. The role of cerebrospinal fluid (CSF) mitochondrial DNA (mtDNA) levels as biomarker in multiple sclerosis (MS) is unknown. We determined CSF mtDNA levels in a cohort of 237 individuals, including patients with MS and clinically isolated syndrome (CIS), inflammatory and non-inflammatory neurological controls, and cognitively healthy controls (HC). mtDNA concentration was measured by droplet digital polymerase chain reaction. CSF mtDNA levels were increased in all pathological conditions compared with HC, though no differences were observed between relapse-onset and progressive MS clinical forms, CIS patients and neurological controls. These findings do not support the determination of CSF mtDNA levels as a useful biomarker in MS clinical practice.
Original languageEnglish
Pages (from-to)1535-1538
JournalMultiple Sclerosis Journal
Publication statusPublished - 1 Oct 2019


  • cerebrospinal fluid
  • droplet digital PCR
  • Mitochondrial DNA
  • multiple sclerosis


Dive into the research topics of 'Cerebrospinal fluid mitochondrial DNA levels in patients with multiple sclerosis'. Together they form a unique fingerprint.

Cite this